Results 261 to 270 of about 45,512 (293)

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

Pigment Cell and Melanoma Research, 2011
Grant McArthur, Rory Wolfe, John Kelly
exaly  

Endorsement of the NRA

New England Journal of Medicine, 1933
openaire   +1 more source

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients

European Journal of Cancer, 2018
Reinhard Dummer, Gerold Schuler, Selma Uğurel   +2 more
exaly  

The NRA:

2019
openaire   +1 more source

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer

International Journal of Cancer, 2015
Alfredo Falcone, Marta Schirripa, Gianluca Masi   +2 more
exaly  

NRA

2012
openaire   +1 more source

Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor

European Journal of Cancer, 2018
Jie Dai, Jiayi Yu, Jun Guo
exaly  

NRAS mutation status is an independent prognostic factor in metastatic melanoma

Cancer, 2012
Richard W. Joseph, Chaan S Ng, Michael A Davies   +2 more
exaly  

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

Pigment Cell and Melanoma Research, 2018
Alain P Algazi, Brian Hinds, Adi Nosrati
exaly  

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma

Journal of the American Academy of Dermatology, 2015
Elisa Funck-Brentano, Elodie Long, Marius Ilié   +2 more
exaly